Application of atractylenolide III in preparation of medicine for treating non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the application field of Atractylodes Lactone III in the preparation of drugs for the treatment of non-alcoholic fatty liver disease, can solve the problem of increasing the risk of coronary artery disease, has not been reported, and the long-term efficacy of pioglitazone needs to be evaluated To achieve the effect of reducing body weight and liver lipid deposition, reducing liver index, and inhibiting lipid deposition

Inactive Publication Date: 2021-11-02
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thiazolidinones, such as pioglitazone and rosiglitazone, can improve transaminases and liver histology in NASH patients, but rosiglitazone increases the risk of coronary artery disease and is strictly restricted in the United States. The long-term efficacy of pioglitazone remains to be evaluated
Metformin remains controversial for the treatment of NAFLD / NASH
However, there is no report about the application of Atractyloid III of the present invention in the preparation of medicines for the treatment of nonalcoholic fatty liver disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atractylenolide III in preparation of medicine for treating non-alcoholic fatty liver disease
  • Application of atractylenolide III in preparation of medicine for treating non-alcoholic fatty liver disease
  • Application of atractylenolide III in preparation of medicine for treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Animal Experiment of Atractyloderm III in Treating Nonalcoholic Fatty Liver Disease

[0035] 1 Experimental materials

[0036]1.1 Experimental animals and cells

[0037] Thirty 5-week-old male C57BL / 6J mice, weighing 14-18g, were sourced from Shanghai Bikai Experimental Animal Co., Ltd., and the license number for experimental animals is: SYXK (Shanghai) 2020-0009. The mice were raised in an SPF-grade barrier system in the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine at a temperature of (24±2)°C and a humidity of 55%. The mice had free access to feed and drinking water. The animal ethics IACUC number is PZSHUTCM210320005.

[0038] 1.2 Experimental drugs and main reagents

[0039] Atractylodes lactone Ⅲ (ATL Ⅲ) was purchased from Shanghai Tongtian Biotechnology Co., Ltd., 60kcal% fat calorie high-fat mouse food (HF60) was purchased from Daitz Biotechnology (Wuxi) Co., Ltd., fatty acid-free bovine serum albumin (BSA), Ole...

Embodiment 2

[0116] Example 2 Cell Experiment of Atractylolide III Therapeutic Effect

[0117] 1 Experimental materials

[0118] 1.1 Experimental cells

[0119] Human liver cancer cell line HepG2 cells were purchased from Nanjing Kebai Biotechnology Co., Ltd.

[0120] 1.2 Experimental drugs and main reagents

[0121] Atractylodes lactone III (ATL III) was purchased from Shanghai Tongtian Biotechnology Co., Ltd. Fatty acid-free bovine serum albumin (BSA), oleic acid (OA) and palmitic acid (PA) were purchased from Sigma-Aldrich, dimethyl sulfoxide ( DMSO) was purchased from Tauto-Biotech, Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin were purchased from Gibco, CCK-8 kit, Compound C, EX 527 were purchased from AbMole, ALT / AST / TG / TC / HDL / LDL / MDA / GSH-Px / SOD / ROS test box, oil red O dye kit, HE dye were purchased from Nanjing Jiancheng Biotechnology Research Institute, RIPA lysate, BCA protein quantification kit , SDS-PAGE gel preparation kit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of atractylenolide III in preparation of a medicine for treating a non-alcoholic fatty liver disease. It is found that atractylenolide III can reduce liver lipid deposition, reduce liver indexes, significantly reduce serum blood fat levels and liver tissue TG and TC levels and activate related signal molecules of an AMPK / SIRT1 signal channel; the MDA level can be reduced, the SOD and GSH-Px levels are increased, and the oxidative stress is improved. The atractylenolide III can inhibit lipid deposition by activating an AMPK / SIRT1 signal channel, reduce the oxidative stress reaction of liver cells, improve the expression level of CPT1A and improve the oxidative stress of mitochondria at the same time, and play a role in treating the non-alcoholic fatty liver disease through the mechanism. The atractylenolide III is a plant-derived chemical substance, the preparation steps are simple, the environmental pollution is small, and the method is suitable for industrial production. Therefore, atractylenolide III can be used for preparing the medicine or health food for treating the non-alcoholic fatty liver disease.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine extracts, in particular to the application of Atractylodes lactone III in the preparation of medicines for treating non-alcoholic fatty liver disease. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by diffuse hepatic steatosis caused by alcohol and other definite liver damage factors. Its pathological process has gone from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), and even further developed into liver fibrosis, liver cirrhosis and even hepatocellular carcinoma. Because the pathogenesis of NAFLD has not been clarified so far, there is no definite and effective therapy for NAFLD, mainly to reduce the risk factors coexisting with cardiovascular disease and metabolic syndrome. [0003] Lifestyle intervention is a treatment method before or in addition to drug treatment, and diet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P1/16A23L33/105C12Q1/02
CPCA61K31/365A61P1/16A23L33/105G01N33/5067A23V2002/00G01N2500/10A23V2200/32
Inventor 李曼高月求孙学华张鑫周振华纪龙珊高亚婷方淼江云李茜
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap